JPH10506782A - 組換え型シチメンチョウヘルペスウイルス、及びその使用 - Google Patents
組換え型シチメンチョウヘルペスウイルス、及びその使用Info
- Publication number
- JPH10506782A JPH10506782A JP8507531A JP50753196A JPH10506782A JP H10506782 A JPH10506782 A JP H10506782A JP 8507531 A JP8507531 A JP 8507531A JP 50753196 A JP50753196 A JP 50753196A JP H10506782 A JPH10506782 A JP H10506782A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- hvt
- recombinant
- fragment
- turkey
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001502481 Meleagrid alphaherpesvirus 1 Species 0.000 title claims abstract description 609
- 239000012634 fragment Substances 0.000 claims abstract description 469
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 claims abstract description 262
- 108091029865 Exogenous DNA Proteins 0.000 claims abstract description 145
- 238000000034 method Methods 0.000 claims abstract description 145
- 239000013598 vector Substances 0.000 claims abstract description 108
- 229960005486 vaccine Drugs 0.000 claims abstract description 101
- 238000003780 insertion Methods 0.000 claims abstract description 79
- 230000037431 insertion Effects 0.000 claims abstract description 79
- 230000003612 virological effect Effects 0.000 claims abstract description 35
- 102000004127 Cytokines Human genes 0.000 claims abstract description 31
- 108090000695 Cytokines Proteins 0.000 claims abstract description 31
- 230000003053 immunization Effects 0.000 claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 383
- 108020004414 DNA Proteins 0.000 claims description 255
- 241000700605 Viruses Species 0.000 claims description 211
- 241001529453 unidentified herpesvirus Species 0.000 claims description 147
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 135
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 133
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 130
- 241000287828 Gallus gallus Species 0.000 claims description 129
- 229920001184 polypeptide Polymers 0.000 claims description 129
- 230000000890 antigenic effect Effects 0.000 claims description 106
- 241000702626 Infectious bursal disease virus Species 0.000 claims description 97
- 210000004027 cell Anatomy 0.000 claims description 97
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 77
- 102000004169 proteins and genes Human genes 0.000 claims description 76
- 108090000288 Glycoproteins Proteins 0.000 claims description 72
- 102000003886 Glycoproteins Human genes 0.000 claims description 70
- 208000015181 infectious disease Diseases 0.000 claims description 65
- 241000711450 Infectious bronchitis virus Species 0.000 claims description 63
- 230000002458 infectious effect Effects 0.000 claims description 54
- 241000588724 Escherichia coli Species 0.000 claims description 52
- 108010050904 Interferons Proteins 0.000 claims description 43
- 101150108190 US2 gene Proteins 0.000 claims description 42
- 108010031571 Marek's disease virus glycoprotein B Proteins 0.000 claims description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
- 102000014150 Interferons Human genes 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 40
- 229940079322 interferon Drugs 0.000 claims description 39
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 37
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 claims description 36
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 33
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 33
- 241000271566 Aves Species 0.000 claims description 32
- 108010006232 Neuraminidase Proteins 0.000 claims description 27
- 102000005348 Neuraminidase Human genes 0.000 claims description 27
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 20
- 101710081079 Minor spike protein H Proteins 0.000 claims description 19
- 108091026890 Coding region Proteins 0.000 claims description 18
- 101710154606 Hemagglutinin Proteins 0.000 claims description 18
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 18
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 18
- 101710176177 Protein A56 Proteins 0.000 claims description 18
- 239000000185 hemagglutinin Substances 0.000 claims description 17
- 208000027312 Bursal disease Diseases 0.000 claims description 16
- 238000011144 upstream manufacturing Methods 0.000 claims description 13
- 108020001507 fusion proteins Proteins 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 12
- 241000286209 Phasianidae Species 0.000 claims description 10
- 101500001537 Avian infectious bursal disease virus Protease VP4 Proteins 0.000 claims description 9
- 229940096437 Protein S Drugs 0.000 claims description 9
- 101710198474 Spike protein Proteins 0.000 claims description 9
- 239000003102 growth factor Substances 0.000 claims description 9
- 101500001538 Avian infectious bursal disease virus Capsid protein VP3 Proteins 0.000 claims description 8
- 102000004889 Interleukin-6 Human genes 0.000 claims description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 7
- 241000218628 Ginkgo Species 0.000 claims description 7
- 235000011201 Ginkgo Nutrition 0.000 claims description 7
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 7
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims description 6
- 102000000588 Interleukin-2 Human genes 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 241000726306 Irus Species 0.000 claims description 6
- 241000282373 Panthera pardus Species 0.000 claims description 6
- 229940100601 interleukin-6 Drugs 0.000 claims description 6
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims description 5
- 101900223469 Avian infectious bronchitis virus Membrane protein Proteins 0.000 claims description 5
- 101710088235 Envelope glycoprotein C homolog Proteins 0.000 claims description 5
- 102000013462 Interleukin-12 Human genes 0.000 claims description 5
- 108010065805 Interleukin-12 Proteins 0.000 claims description 5
- 206010006451 bronchitis Diseases 0.000 claims description 5
- 229940117681 interleukin-12 Drugs 0.000 claims description 5
- 229940031348 multivalent vaccine Drugs 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 108060003393 Granulin Proteins 0.000 claims description 3
- 101900190364 Infectious laryngotracheitis virus Envelope glycoprotein B Proteins 0.000 claims description 3
- 102000053187 Glucuronidase Human genes 0.000 claims description 2
- 108010060309 Glucuronidase Proteins 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 102000002467 interleukin receptors Human genes 0.000 claims 2
- 108010093036 interleukin receptors Proteins 0.000 claims 2
- 108010077644 Marek's disease virus glycoprotein D Proteins 0.000 claims 1
- 238000006178 Rupe rearrangement reaction Methods 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 238000009395 breeding Methods 0.000 claims 1
- 230000001488 breeding effect Effects 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 230000007923 virulence factor Effects 0.000 claims 1
- 239000000304 virulence factor Substances 0.000 claims 1
- 238000002649 immunization Methods 0.000 abstract description 6
- 235000013330 chicken meat Nutrition 0.000 description 119
- 108091027544 Subgenomic mRNA Proteins 0.000 description 116
- 239000013612 plasmid Substances 0.000 description 96
- 108091007433 antigens Proteins 0.000 description 81
- 102000036639 antigens Human genes 0.000 description 78
- 239000000427 antigen Substances 0.000 description 77
- 235000018102 proteins Nutrition 0.000 description 71
- 208000006758 Marek Disease Diseases 0.000 description 53
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 51
- 244000144977 poultry Species 0.000 description 43
- 235000013594 poultry meat Nutrition 0.000 description 43
- 150000001413 amino acids Chemical class 0.000 description 42
- 101150066555 lacZ gene Proteins 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 35
- 244000052769 pathogen Species 0.000 description 35
- 108020004511 Recombinant DNA Proteins 0.000 description 34
- 108700021117 chicken MGF Proteins 0.000 description 34
- 230000001717 pathogenic effect Effects 0.000 description 34
- 239000000523 sample Substances 0.000 description 32
- 102000004190 Enzymes Human genes 0.000 description 31
- 108090000790 Enzymes Proteins 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 206010044302 Tracheitis Diseases 0.000 description 30
- 238000002474 experimental method Methods 0.000 description 28
- 238000004519 manufacturing process Methods 0.000 description 28
- 230000002103 transcriptional effect Effects 0.000 description 26
- 238000002255 vaccination Methods 0.000 description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 25
- 241000283073 Equus caballus Species 0.000 description 25
- 102100026189 Beta-galactosidase Human genes 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 24
- 241000700584 Simplexvirus Species 0.000 description 23
- 238000001890 transfection Methods 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 21
- 239000002299 complementary DNA Substances 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 238000012761 co-transfection Methods 0.000 description 20
- 244000005700 microbiome Species 0.000 description 20
- 238000003752 polymerase chain reaction Methods 0.000 description 17
- 238000002105 Southern blotting Methods 0.000 description 16
- 101500001532 Avian infectious bursal disease virus Capsid protein VP2 Proteins 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000010276 construction Methods 0.000 description 15
- 230000028993 immune response Effects 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 241000283690 Bos taurus Species 0.000 description 14
- 101150008820 HN gene Proteins 0.000 description 14
- 238000010367 cloning Methods 0.000 description 14
- 230000008488 polyadenylation Effects 0.000 description 14
- 108091008146 restriction endonucleases Proteins 0.000 description 14
- 208000010359 Newcastle Disease Diseases 0.000 description 13
- 101150050057 UL43 gene Proteins 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 13
- 230000006801 homologous recombination Effects 0.000 description 13
- 238000002744 homologous recombination Methods 0.000 description 13
- 239000008188 pellet Substances 0.000 description 13
- 239000003550 marker Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 241000712461 unidentified influenza virus Species 0.000 description 12
- 210000001161 mammalian embryo Anatomy 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 230000006798 recombination Effects 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 101000645498 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_10220 Proteins 0.000 description 10
- 241000711895 Bovine orthopneumovirus Species 0.000 description 10
- 101001132313 Clostridium pasteurianum 34.2 kDa protein in rubredoxin operon Proteins 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
- 101000618325 Enterobacteria phage T4 Uncharacterized 12.4 kDa protein in mobB-Gp55 intergenic region Proteins 0.000 description 10
- 101000653284 Enterobacteria phage T4 Uncharacterized 9.4 kDa protein in Gp31-cd intergenic region Proteins 0.000 description 10
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 10
- 101000758676 Pyrococcus woesei Uncharacterized 24.7 kDa protein in gap 5'region Proteins 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 101150029683 gB gene Proteins 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000005215 recombination Methods 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 101150034814 F gene Proteins 0.000 description 9
- 229940031416 bivalent vaccine Drugs 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 201000009837 laryngotracheitis Diseases 0.000 description 9
- 230000010076 replication Effects 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 241000588807 Bordetella Species 0.000 description 7
- 241000223924 Eimeria Species 0.000 description 7
- 241001500351 Influenzavirus A Species 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 108010076039 Polyproteins Proteins 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 101150036031 gD gene Proteins 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 210000004989 spleen cell Anatomy 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 241000712005 Bovine respirovirus 3 Species 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000015696 Interleukins Human genes 0.000 description 6
- 108010063738 Interleukins Proteins 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 206010046865 Vaccinia virus infection Diseases 0.000 description 6
- 108020005202 Viral DNA Proteins 0.000 description 6
- 239000013601 cosmid vector Substances 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 239000002356 single layer Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 6
- 208000007089 vaccinia Diseases 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 241000238876 Acari Species 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 241000242722 Cestoda Species 0.000 description 5
- 241000711573 Coronaviridae Species 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 241000948219 Histomonas Species 0.000 description 5
- 241000244206 Nematoda Species 0.000 description 5
- 241001674048 Phthiraptera Species 0.000 description 5
- 241000607142 Salmonella Species 0.000 description 5
- 241000224526 Trichomonas Species 0.000 description 5
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 244000052637 human pathogen Species 0.000 description 5
- -1 inleukin Tarleukin 9 Proteins 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108090000565 Capsid Proteins Proteins 0.000 description 4
- 102100023321 Ceruloplasmin Human genes 0.000 description 4
- 241000725585 Chicken anemia virus Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 241000223960 Plasmodium falciparum Species 0.000 description 4
- 241000702263 Reovirus sp. Species 0.000 description 4
- 241000702670 Rotavirus Species 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 241000242541 Trematoda Species 0.000 description 4
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 201000002491 encephalomyelitis Diseases 0.000 description 4
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- LINMATFDVHBYOS-MBJXGIAVSA-N (2s,3r,4s,5r,6r)-2-[(5-bromo-1h-indol-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C=C12 LINMATFDVHBYOS-MBJXGIAVSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 241000701081 Equid alphaherpesvirus 1 Species 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 241000606860 Pasteurella Species 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 101150075200 S-2 gene Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 101150117115 V gene Proteins 0.000 description 3
- 101150093578 VP2 gene Proteins 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 230000007503 antigenic stimulation Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940028617 conventional vaccine Drugs 0.000 description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 101710186708 Agglutinin Proteins 0.000 description 2
- 102100022987 Angiogenin Human genes 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 101150076489 B gene Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 241000680578 Canid alphaherpesvirus 1 Species 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 208000026845 Cochlear disease Diseases 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 241000243990 Dirofilaria Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 101900264058 Escherichia coli Beta-galactosidase Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 241000700662 Fowlpox virus Species 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101710146024 Horcolin Proteins 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 2
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102100039897 Interleukin-5 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000000585 Interleukin-9 Human genes 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 101710189395 Lectin Proteins 0.000 description 2
- 241001550390 Leptospira interrogans serovar Canicola Species 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
- 101710179758 Mannose-specific lectin Proteins 0.000 description 2
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 2
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 2
- 241000934179 Meria <ascomycete> Species 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 102000004140 Oncostatin M Human genes 0.000 description 2
- 108090000630 Oncostatin M Proteins 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 241001442654 Percnon planissimum Species 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101710194807 Protective antigen Proteins 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 241000282695 Saimiri Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 101150037787 Sting gene Proteins 0.000 description 2
- 101150060741 Sting1 gene Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 101150009795 UL54 gene Proteins 0.000 description 2
- 101150081415 UL55 gene Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000006154 adenylylation Effects 0.000 description 2
- 239000000910 agglutinin Substances 0.000 description 2
- 108010072788 angiogenin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000000078 claw Anatomy 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 101150030521 gI gene Proteins 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940074383 interleukin-11 Drugs 0.000 description 2
- 229940076264 interleukin-3 Drugs 0.000 description 2
- 229940100602 interleukin-5 Drugs 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940118526 interleukin-9 Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 108010091748 peptide A Proteins 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 229940031418 trivalent vaccine Drugs 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- AEELXMHQIJJMKP-QWWZWVQMSA-N (2r,3r)-3-sulfanylbutane-1,2,4-triol Chemical compound OC[C@@H](O)[C@H](S)CO AEELXMHQIJJMKP-QWWZWVQMSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- KBDIEUYACKKLIJ-UHFFFAOYSA-N 2-isocyanatoguanidine Chemical compound NC(=N)NN=C=O KBDIEUYACKKLIJ-UHFFFAOYSA-N 0.000 description 1
- 108010055961 AGGCCT-specific type II deoxyribonucleases Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 102100021253 Antileukoproteinase Human genes 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 241000796533 Arna Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000008921 Avian coronavirus Species 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 101100459438 Caenorhabditis elegans nac-1 gene Proteins 0.000 description 1
- 241000701101 Canine adenovirus 1 Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 1
- 101100394030 Dictyostelium discoideum gxcB gene Proteins 0.000 description 1
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 208000010772 Dog disease Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000230501 Equine herpesvirus sp. Species 0.000 description 1
- 241001452028 Escherichia coli DH1 Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- 101000693916 Gallus gallus Albumin Proteins 0.000 description 1
- 102000034354 Gi proteins Human genes 0.000 description 1
- 108091006101 Gi proteins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101800000342 Glycoprotein C Proteins 0.000 description 1
- 101710181600 Glycoprotein gp2 Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 229940124841 Herpesvirus vaccine Drugs 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
- 101900111632 Human herpesvirus 1 Envelope glycoprotein C Proteins 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 101900208483 Human parainfluenza 3 virus Fusion glycoprotein F0 Proteins 0.000 description 1
- 101150027427 ICP4 gene Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100021592 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 1
- 229910001374 Invar Inorganic materials 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 101710173438 Late L2 mu core protein Proteins 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 108091036060 Linker DNA Proteins 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 101150003837 MGF gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000948165 Milk vetch dwarf virus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091060545 Nonsense suppressor Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 102100039277 Pleiotrophin Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 1
- 208000027954 Poultry disease Diseases 0.000 description 1
- 101710188053 Protein D Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 101710132893 Resolvase Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108010082545 Secretory Leukocyte Peptidase Inhibitor Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000700565 Swinepox virus Species 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 241001223089 Tremovirus A Species 0.000 description 1
- 241000220979 Trichomonas sp. Species 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000981595 Zoysia japonica Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 241000701792 avian adenovirus Species 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000024753 bloody sputum Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 208000014058 canine distemper Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000010717 cat disease Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- UFJPAQSLHAGEBL-RRKCRQDMSA-N dITP Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(N=CNC2=O)=C2N=C1 UFJPAQSLHAGEBL-RRKCRQDMSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100994 interleukin-7 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- KRZWEBVPFGCYMY-UHFFFAOYSA-M methylmercury(1+);hydroxide Chemical compound [OH-].[Hg+]C KRZWEBVPFGCYMY-UHFFFAOYSA-M 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 108010024226 placental ribonuclease inhibitor Proteins 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- HJRIWDYVYNNCFY-UHFFFAOYSA-M potassium;dimethylarsinate Chemical compound [K+].C[As](C)([O-])=O HJRIWDYVYNNCFY-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012070 reactive reagent Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- GFWRVVCDTLRWPK-KPKJPENVSA-N sofalcone Chemical compound C1=CC(OCC=C(C)C)=CC=C1\C=C\C(=O)C1=CC=C(OCC=C(C)C)C=C1OCC(O)=O GFWRVVCDTLRWPK-KPKJPENVSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 101150069452 z gene Proteins 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16341—Use of virus, viral particle or viral elements as a vector
- C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.サイトカインをコードする外来性DNA配列を具備し、該配列がシチメン チョウ・ヘルペスウイルスのゲノムのEcoRI#9断片中のXhoI部位を具備した挿 入領域へ挿入された組換え型シチメンチョウ・ヘルペスウイルスであって、サイ トカインをコードした前記の外来性DNA配列が、シチメンチョウ・ヘルペスウ イルスに感染した宿主細胞内で発現されることが可能な、上記の組換え型シチメ ンチョウ・ヘルペスウイルス。 2.前記のサイトカインが、ニワトリの骨髄単球性成長因子(cMGF)、ニワト リのインターフェロン(cIFN)、インターロイキン-2、インターロイキン-6、イ ンターロイキン-12、インターフェロン群、顆粒球−マクロファージコロニー刺 激性因子、またはインターロイキン受容体であることを特徴とする、請求項1に 記載の組換え型シチメンチョウ・ヘルペスウイルス。 3.第二の外来性DNA配列を更に具備した、請求項1に記載の組換え型シチ メンチョウ・ヘルペスウイルス。 4.前記の外来性DNA配列が、ポリペプチドをコードしていることを特徴と する、請求項3に記載の組換え型シチメンチョウ・ヘルペスウイルス。 5.前記のポリペプチドが、抗原性であることを特徴とする、請求項4に記載 の組換え型シチメンチョウ・ヘルペスウイルス。 6.前記のポリペプチドが大腸菌(E.coli)のベータガラクトシダーゼである ことを特徴とする、請求項4に記載の組換え型シチメンチョウ・ヘルペスウイル ス。 7.S-HVT-144と命名されている、請求項2に記載の組換え型シチメンチョウ ・ヘルペスウイルス。 8.抗原性ポリペプチドをコードする、前記の外来性DNA配列が、US2遺伝 子内のユニークなStuI部位を具備するシチメンチョウ・ヘルペスウイルスの挿入 領域へ挿入されていることを特徴とする、請求項5に記載の組換え型シチメンチ ョウ・ヘルペスウイルス。 9.前記のDNA配列が、以下のものよりなる群から選択される抗原性ポリペ プチドを具備することを特徴とする、請求項8に記載の組換え型シチメンチョウ ・ヘルペスウイルス:マレック病ウイルス、ニューカッスル病ウイルス、伝染性 喉頭気管炎ウイルス、伝染性気管支炎ウイルス、伝染性粘液嚢病ウイルス。 10.前記の外来性DNA配列が、マレック病ウイルスの糖タンパク質A、マ レック病ウイルスの糖タンパク質B、またはマレック病ウイルスの糖タンパク質D をコードすることを特徴とする、請求項9に記載の組換え型シチメンチョウ・ヘ ルペスウイルス。 11.前記の外来性DNA配列が、ニューカッスル病ウイルスの融合タンパク 質、またはニューカッスル病ウイルスの血球凝集素・ノイラミニダーゼをコード することを特徴とする、請求項9に記載の組換え型シチメンチョウ・ヘルペスウ イルス。 12.前記の外来性DNA配列が、伝染性喉頭気管炎ウイルスの糖タンパク質 B、伝染性喉頭気管炎ウイルスの糖タンパク質I、または伝染性喉頭気管炎ウイル スの糖タンパク質Dをコードすることを特徴とする、請求項9に記載の組換え型 シチメンチョウ・ヘルペスウイルス。 13.前記の外来性DNA配列が、伝染性気管支炎ウイルスのスパイクタンパ ク質、または伝染性気管支炎ウイルスのマトリックスタンパク質をコードするこ とを特徴とする、請求項9に記載の組換え型シチメンチョウ・ヘルペスウイルス 。 14.前記の外来性DNA配列が、伝染性粘液嚢病ウイルスのVP2、伝染性粘 液嚢病ウイルスのVP3、または伝染性粘液嚢病ウイルスのVP4をコードすること を特徴とする、請求項9に記載の組換え型シチメンチョウ・ヘルペスウイルス。 15.前記のサイトカインが、内在性の上流ヘルペスウイルスプロモータの制 御下にあることを特徴とする、請求項1に記載の組換え型シチメンチョウ・ヘル ペスウイルス。 16.前記のサイトカインが、異種の上流プロモータ制御下にあることを特徴 とする、請求項15に記載の組換え型シチメンチョウ・ヘルペスウイルス。 17.前記のプロモータが、PRV gX、HSV-1アルファ4、HCMV極初期、MDV gA 、MDV gB、MDV gD、ILT gB、BHV-1.1 VP8、及びILT gDの中から選択されること を特徴とする、請求項15に記載の組換え型シチメンチョウ・ヘルペスウイルス 。 18.以下の(a)〜(c)を必須的に有する二本鎖DNA分子を具備した、シチメ ンチョウ・ヘルペスウイルスのゲノムの中に、サイトカインをコードする外来性 DNA配列を挿入することによって、組換え型シチメンチョウ・ヘルペスウイル スを産生させるための相同性ベクタ: (a)通常はシチメンチョウ・ヘルペスウイルスのゲノム内には存在しない外来 性の二本鎖DNA; (b)シチメンチョウ・ヘルペスウイルスのゲノムのコード領域の、EcoRI#9断 片の一方の末端に位置する、ウイルスゲノムに対して相同性があって、前記外来 性DNAの一方の末端に存在するシチメンチョウ・ヘルペスウイルス2本鎖DN A; (c)シチメンチョウ・ヘルペスウイルスのゲノムのコード領域の、EcoRI#9断 片のもう一方の末端に位置する、ウイルスゲノムに対して相同性があって、前記 外来性DNAのもう一方の末端に存在する、シチメンチョウ・ヘルペスウイルス 2本鎖DNA。 19.前記のサイトカインが、ニワトリの骨髄単球性成長因子(cMGF)、ニワ トリのインターフェロン(cIFN)、インターロイキン-2、インターロイキン-6、 インターロイキン-12、インターフェロン群、顆粒球・マクロファージコロニー 刺激性因子、またはインターロイキン受容体であることを特徴とする、請求項1 8に記載の組換え型シチメンチョウ・ヘルペスウイルス。 20.抗原性ポリペプチドをコードする第二の外来性DNA配列を更に具備し た、請求項18に記載の相同性ベクタ。 21.前記の抗原性ポリペプチドが、必須的に以下のものよりなる群から選択 されることを特徴とする、請求項20に記載の相同性ベクタ:マレック病ウイル ス、ニューカッスル病ウイルス、伝染性喉頭気管炎ウイルス、伝染性気管支炎ウ イルス、伝染性粘液嚢病ウイルス。 22.前記の抗原性ポリペプチドが、必須的に以下のものよりなる群から選択 されることを特徴とする、請求項20に記載の相同性ベクタ:マレック病ウイル スの糖タンパク質A、マレック病ウイルスの糖タンパク質B、マレック病ウイルス の糖タンパク質D、ニューカッスル病ウイルスの融合タンパク質、ニュー カッスル病ウイルスの血球凝集素・ノイラミニダーゼ、伝染性喉頭気管炎ウイル スの糖タンパク質B、伝染性喉頭気管炎ウイルスの糖タンパク質I、伝染性喉頭気 管炎ウイルスの糖タンパク質D、伝染性気管支炎ウイルスのスパイクタンパク質 、伝染性気管支炎ウイルスのマトリックスタンパク質、伝染性粘液嚢病ウイルス のVP2、伝染性粘液嚢病ウイルスのVP3、及び伝染性粘液嚢病ウイルスのVP4。 23.前記の外来性DNA配列が、スクリーニング可能な標識をコードするこ とを特徴とする、請求項20に記載の相同性ベクタ。 24.前記のスクリーニング可能な標識が、大腸菌(E.coli)のベータガラク トシダーゼ、または大腸菌(E.coli)のベータグルクロニダーゼであることを特 徴とする、請求項23に記載の相同性ベクタ。 25.751−87.A8と命名されている、請求項18に記載の相同性ベクタ 。 26.761−07.A1と命名されている、請求項18に記載の相同性ベクタ 。 27.トリをマレック病ウイルスに対して免疫にするのに有益なワクチンであ って、請求項10に記載の効果的な免疫量の組換え型シチメンチョウ・ヘルペス ウイルス、及び適切な担体を具備したワクチン。 28.トリをニューカッスル病ウイルスに対して免疫にするのに有益なワクチ ンであって、請求項11に記載の効果的な免疫量の組換え型シチメンチョウ・ヘ ルペスウイルス、及び適切な担体を具備したワクチン。 29.トリを伝染性喉頭気管炎ウイルスに対して免疫にするのに有益なワクチ ンであって、請求項12に記載の効果的な免疫量の組換え型シチメンチョウ・ヘ ルペスウイルス、及び適切な担体を具備したワクチン。 30.トリをマレック病ウイルス、及びニューカッスル病ウイルスに対して免 疫にするのに有益な多価ワクチンであって、請求項11に記載の効果的な免疫量 の組換え型シチメンチョウ・ヘルペスウイルスを具備したワクチン。 31.トリをマレック病ウイルスに対して免疫するための方法であって、請求 項27に記載の、効果的な投薬量のワクチンをトリに投与することを具備した方 法。 32.請求項1に記載の組換え型シチメンチョウ・ヘルペスウイルスに感染し た宿主細胞。 33.前記の宿主細胞がトリの細胞であることを特徴とする、請求項32に記 載の宿主細胞。 34.シチメンチョウ・ヘルペスウイルスのユニークな長いウイルスゲノム領 域とマレック病ウイルスのユニークな短い領域とを具備した、シチメンチョウ・ ヘルペスウイルスとマレック病ウイルスとの組換え体キメラ。 35.前記の外来性DNA配列が、シチメンチョウ・ヘルペスウイルスのゲノ ムのEcoRI#9断片中へ挿入されていて、またシチメンチョウ・ヘルペスウイル スに感染した宿主細胞内で発現することが可能であることを特徴とする、請求項 34に記載の、シチメンチョウ・ヘルペスウイルスとマレック病ウイルスとの組 換え体キメラ。 36.前記の外来性DNA配列が、ポリペプチドをコードすることを特徴とす る、請求項35に記載の、シチメンチョウ・ヘルペスウイルスとマレック病ウイ ルスとの組換え体キメラ。 37.前記の外来性DNA配列がサイトカインをコードすることを特徴とする 、請求項36に記載の、シチメンチョウ・ヘルペスウイルスとマレック病ウイル スとの組換え体キメラ。 38.前記のサイトカインがニワトリ骨髄単球性成長因子(cMGF)、またはニ ワトリのインターフェロン(cIFN)であることを特徴とする、請求項37に記載 の、シチメンチョウ・ヘルペスウイルスとマレック病ウイルスとの組換え体キメ ラ。 39.抗原性ポリペプチドをコードする外来性DNAを更に具備した、請求項 38に記載の、シチメンチョウ・ヘルペスウイルスとマレック病ウイルスとの組 換え体キメラであって、該抗原性ポリペプチドが、マレック病ウイルス、ニュー カッスル病ウイルス、伝染性喉頭気管炎ウイルス、伝染性気管支炎ウイルス、及 び伝染性粘液嚢病ウイルスからなる群より選択される、上記のキメラ。 40.S-HVT-145と命名されている、請求項39に記載の組換え型シチメンチ ョウ・ヘルペスウイルス。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/288,065 | 1994-08-09 | ||
US08/288,065 US5961982A (en) | 1985-09-06 | 1994-08-09 | Recombinant herpesvirus of turkeys and uses thereof |
US08/362,240 | 1994-12-22 | ||
US08/362,240 US5965138A (en) | 1985-09-06 | 1994-12-22 | Recombinant chimeric virus and uses thereof |
PCT/US1995/010245 WO1996005291A1 (en) | 1994-08-09 | 1995-08-09 | Recombinant herpesvirus of turkeys and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005274301A Division JP4339835B2 (ja) | 1994-08-09 | 2005-09-21 | 組換え型シチメンチョウ・ヘルペスウイルス、及びその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10506782A true JPH10506782A (ja) | 1998-07-07 |
JP3756950B2 JP3756950B2 (ja) | 2006-03-22 |
Family
ID=26964815
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50753196A Expired - Fee Related JP3756950B2 (ja) | 1994-08-09 | 1995-08-09 | 組換え型シチメンチョウヘルペスウイルス、及びその使用 |
JP2005274301A Expired - Lifetime JP4339835B2 (ja) | 1994-08-09 | 2005-09-21 | 組換え型シチメンチョウ・ヘルペスウイルス、及びその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005274301A Expired - Lifetime JP4339835B2 (ja) | 1994-08-09 | 2005-09-21 | 組換え型シチメンチョウ・ヘルペスウイルス、及びその使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5965138A (ja) |
EP (2) | EP1801204B1 (ja) |
JP (2) | JP3756950B2 (ja) |
AT (2) | ATE498006T1 (ja) |
AU (1) | AU711815C (ja) |
CA (1) | CA2196570C (ja) |
DE (2) | DE69536138D1 (ja) |
DK (1) | DK0776361T3 (ja) |
ES (1) | ES2278382T3 (ja) |
MX (1) | MX9700833A (ja) |
WO (1) | WO1996005291A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002541797A (ja) * | 1999-04-09 | 2002-12-10 | シェーリング−プラウ・リミテッド | 新規な組換えヘルペスウイルスおよび変異体ヘルペスウイルス |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990002802A2 (en) * | 1988-09-13 | 1990-03-22 | Institute For Animal Health Limited | Viral nucleotide sequences |
US6183753B1 (en) * | 1994-08-09 | 2001-02-06 | Schering-Plough Veterinary Corp. | Recombinant chimeric virus and uses thereof |
US6913751B2 (en) * | 1992-06-12 | 2005-07-05 | Schering-Plough Veterinary Corporation | Recombinant avian herpesvirus useful in vaccine production |
US6984728B2 (en) * | 1993-09-24 | 2006-01-10 | Schering Corporation | Recombinant infectious laryngotracheitis virus and uses thereof |
FR2728794B1 (fr) * | 1994-12-30 | 1997-03-21 | Rhone Merieux | Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro |
FR2728795B1 (fr) * | 1994-12-30 | 1997-03-21 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire |
DE69836557T2 (de) | 1997-10-03 | 2007-09-20 | Zeon Corp. | Rekombinanten des infektiösen vogel-herpesvirus und rekombinante impfstoffe, die unter dessen verwendung hergestellt wurden |
US6506385B1 (en) | 1998-04-17 | 2003-01-14 | Embrex, Inc. | Live vaccines and methods of treatment therewith |
CA2388822A1 (en) * | 1999-10-29 | 2001-05-10 | Human Genome Sciences, Inc. | 27 human secreted proteins |
US6516246B2 (en) * | 2000-09-11 | 2003-02-04 | Mimicking Man Manually, Inc. | Method and system for determining native neurological dominant hemisphere |
US7314715B2 (en) * | 2001-06-14 | 2008-01-01 | Schering-Plough Animal Health Corporation | Recombinant avian herpesvirus useful in vaccine production |
US6764684B2 (en) | 2001-09-28 | 2004-07-20 | Zeon Corporation | Avian herpesvirus-based recombinant infectious bursal disease vaccine |
US7205398B2 (en) * | 2002-05-24 | 2007-04-17 | Schering-Plough Animal Health Corporation | Eta-1 gene and methods for use |
US7897146B2 (en) | 2003-11-17 | 2011-03-01 | Crusade Laboratories Limited | Treatment using herpes simplex virus |
GB0326798D0 (en) | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
JP2007511216A (ja) | 2003-11-17 | 2007-05-10 | クルセイド ラボラトリーズ リミテッド | 変異ウイルス |
MX2007012383A (es) * | 2005-04-08 | 2007-11-07 | Bayer Bioscience Nv | Evento elite a2704-12 y metodos y equipos para identificar dicho evento en muestras biologicas. |
US20080241188A1 (en) | 2007-03-30 | 2008-10-02 | Zeon Corporation | Turkey herpesvirus vectored recombinant containing avian influenza genes |
WO2009156367A1 (en) * | 2008-06-23 | 2009-12-30 | Intervet International B.V. | Recombinant herpesvirus of turkeys encoding for interleukin-12 |
US9089360B2 (en) | 2008-08-06 | 2015-07-28 | Ethicon Endo-Surgery, Inc. | Devices and techniques for cutting and coagulating tissue |
BR112014008161A2 (pt) | 2011-10-21 | 2017-04-11 | Intervet Int Bv | vírus da doença de marek não patogênico recombinante, método para a preparação do mesmo, molécula do ácido nucleico, célula hospedeira, vacina para aves domésticas, método para a preparação de uma vacina, uso de um vírus da doença de marek não patogênico recombinante, e, método de vacinação de aves domésticas |
ES2700243T3 (es) | 2011-10-21 | 2019-02-14 | Intervet Int Bv | Construcciones del virus de la enfermedad de Marek recombinantes no patógenas que codifican antígenos del virus de la laringotraqueitis infecciosa y del virus de la enfermedad de Newcastle |
EP2644702A1 (en) | 2012-03-30 | 2013-10-02 | Ceva Sante Animale | Multivalent recombinant avian herpes virus and vaccine for immunizing avian species |
AR097029A1 (es) * | 2013-07-26 | 2016-02-17 | Intervet Int Bv | Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune |
AR103245A1 (es) | 2014-12-24 | 2017-04-26 | Intervet Int Bv | Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada |
JP7046014B2 (ja) | 2016-06-17 | 2022-04-01 | インターベット インターナショナル ベー. フェー. | 伝染性喉頭気管炎ウイルスおよび伝染性ファブリキウス嚢病ウイルスの抗原をコードする組換え非病原性マレック病ウイルスコンストラクト |
CN117357642A (zh) | 2016-12-14 | 2024-01-09 | 勃林格殷格翰动物保健美国公司 | 表达禽病原体的多种抗原的重组hvt载体及其用途 |
CN111542599A (zh) | 2017-10-12 | 2020-08-14 | 英特维特国际股份有限公司 | 编码多种异源抗原的重组非致病性马尔克氏病病毒构建体 |
WO2021050701A1 (en) | 2019-09-11 | 2021-03-18 | Zoetis Services Llc | Recombinant herpesvirus of turkey vectors expressing antigens of avian pathogens and uses thereof |
BR112022010825A2 (pt) | 2019-12-20 | 2022-08-23 | Intervet Int Bv | Vacina de vetor hvt multivalente |
IL299033A (en) | 2020-06-17 | 2023-02-01 | Boehringer Ingelheim Vetmedica Gmbh | Recombinant HVT vectors expressing influenza hemagglutinin and immunogenic compounds, production and uses thereof |
CN116648259A (zh) | 2020-12-24 | 2023-08-25 | 英特维特国际股份有限公司 | 多价hvt载体疫苗 |
WO2023213946A1 (en) | 2022-05-05 | 2023-11-09 | Intervet International B.V. | New multivalent hvt vector vaccine |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4859587A (en) * | 1984-06-04 | 1989-08-22 | Institut Merieux | Recombinant herpes simplex viruses, vaccines and methods |
US4877737A (en) * | 1985-09-06 | 1989-10-31 | Prutech Research And Development Partnership | Attenuated pseudorabies virus which has a deletion in at least a portion of a repeat sequence and vaccine containing same |
US5223424A (en) * | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
US5047237A (en) * | 1985-09-06 | 1991-09-10 | Prutech Research And Development Partnership | Attenuated pseudorabies virus having a deletion of at least a portion of a gene encoding an antigenic, nonessential protein, vaccine containing same and methods of identifying animals vaccinated with the vaccine |
US5928648A (en) * | 1985-09-06 | 1999-07-27 | Syntro Corporation | Recombinant herpesvirus of turkeys and uses thereof |
DE3853819T2 (de) * | 1987-03-19 | 1995-09-21 | Synergen Inc | Virales vektorsystem zum einführen fremder dns-expressionserzeugnisse in gallinaceenvögeln. |
EP0332677B1 (en) * | 1987-07-27 | 1995-07-19 | Syntro Corporation | Attenuated herpes viruses, herpes viruses which include foreign dna encoding an amino acid sequence and vaccines containing same |
JP2583115B2 (ja) * | 1988-09-10 | 1997-02-19 | 財団法人化学及血清療法研究所 | 組換えマレック病ウイルスおよびその製法 |
WO1990002802A2 (en) * | 1988-09-13 | 1990-03-22 | Institute For Animal Health Limited | Viral nucleotide sequences |
US5225336A (en) * | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
EP0431668B1 (en) * | 1989-12-04 | 1995-02-15 | Akzo Nobel N.V. | Recombinant herpesvirus of turkeys and live vector vaccines derived thereof |
FR2659349B1 (fr) * | 1990-03-12 | 1993-12-24 | Rhone Merieux | Virus herpes recombinants notamment pour la realisation de vaccins, leur procede de preparation, les plasmides realises au cours de ce procede et les vaccins obtenus. |
ES2056565T3 (es) * | 1990-07-30 | 1994-10-01 | Akzo Nobel Nv | Virus recombinante de la enfermedad de marek. |
WO1992003554A1 (en) * | 1990-08-24 | 1992-03-05 | Arthur Webster Pty. Ltd. | Infectious laryngotracheitis virus vaccine |
US5252717A (en) * | 1990-08-24 | 1993-10-12 | Board Of Trustees Operating Michigan State University | Marek's disease herpesvirus DNA segments encoding glycoproteins, gD, gI and gE |
FR2666589B1 (fr) * | 1990-09-07 | 1994-08-05 | Rhone Merieux | Nouveaux virus herpes recombinants, vaccin a base de ces recombinants, leur procede de preparation, genes, vecteurs et plasmides utilises dans ce procede. |
EP0486106A3 (en) * | 1990-11-16 | 1992-12-23 | Akzo N.V. | Marek's disease virus vaccine |
US5240703A (en) * | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
WO1992015672A1 (en) * | 1991-03-07 | 1992-09-17 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5853733A (en) * | 1993-02-26 | 1998-12-29 | Syntro Corporation | Recombinant herpesvirus of turkeys and uses thereof |
FR2697534A1 (fr) * | 1992-11-02 | 1994-05-06 | Rhone Merieux | Virus herpès de la dinde recombinant pour la réalisation de vaccin de la maladie de Gumboro, son procédé de préparation et vaccin obtenu. |
-
1994
- 1994-12-22 US US08/362,240 patent/US5965138A/en not_active Expired - Lifetime
-
1995
- 1995-08-09 ES ES95930814T patent/ES2278382T3/es not_active Expired - Lifetime
- 1995-08-09 DE DE69536138T patent/DE69536138D1/de not_active Expired - Lifetime
- 1995-08-09 JP JP50753196A patent/JP3756950B2/ja not_active Expired - Fee Related
- 1995-08-09 MX MX9700833A patent/MX9700833A/es unknown
- 1995-08-09 AU AU34053/95A patent/AU711815C/en not_active Expired
- 1995-08-09 EP EP06026820A patent/EP1801204B1/en not_active Expired - Lifetime
- 1995-08-09 AT AT06026820T patent/ATE498006T1/de not_active IP Right Cessation
- 1995-08-09 CA CA2196570A patent/CA2196570C/en not_active Expired - Lifetime
- 1995-08-09 EP EP95930814A patent/EP0776361B1/en not_active Expired - Lifetime
- 1995-08-09 WO PCT/US1995/010245 patent/WO1996005291A1/en active IP Right Grant
- 1995-08-09 DE DE69535359T patent/DE69535359T2/de not_active Expired - Lifetime
- 1995-08-09 DK DK95930814T patent/DK0776361T3/da active
- 1995-08-09 AT AT95930814T patent/ATE350467T1/de not_active IP Right Cessation
-
2005
- 2005-09-21 JP JP2005274301A patent/JP4339835B2/ja not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002541797A (ja) * | 1999-04-09 | 2002-12-10 | シェーリング−プラウ・リミテッド | 新規な組換えヘルペスウイルスおよび変異体ヘルペスウイルス |
Also Published As
Publication number | Publication date |
---|---|
EP0776361A4 (en) | 2003-06-04 |
JP3756950B2 (ja) | 2006-03-22 |
US5965138A (en) | 1999-10-12 |
AU711815B2 (en) | 1999-10-21 |
CA2196570A1 (en) | 1996-02-22 |
WO1996005291A1 (en) | 1996-02-22 |
MX9700833A (es) | 1997-06-28 |
DE69535359T2 (de) | 2007-10-11 |
CA2196570C (en) | 2010-10-12 |
EP0776361B1 (en) | 2007-01-03 |
EP1801204B1 (en) | 2011-02-09 |
JP4339835B2 (ja) | 2009-10-07 |
DE69536138D1 (de) | 2011-03-24 |
ES2278382T3 (es) | 2007-08-01 |
EP1801204A1 (en) | 2007-06-27 |
DK0776361T3 (da) | 2007-04-30 |
AU3405395A (en) | 1996-03-07 |
ATE498006T1 (de) | 2011-02-15 |
EP0776361A1 (en) | 1997-06-04 |
AU711815C (en) | 2003-02-20 |
JP2006055171A (ja) | 2006-03-02 |
ATE350467T1 (de) | 2007-01-15 |
DE69535359D1 (de) | 2007-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10506782A (ja) | 組換え型シチメンチョウヘルペスウイルス、及びその使用 | |
US5187087A (en) | Recominbant herpesvirus of turkeys and live vector vaccines derived thereof | |
AU734085B2 (en) | Recombinant live avian vaccine, using as vector the avian infectious laryngotracheitis virus. | |
US5853733A (en) | Recombinant herpesvirus of turkeys and uses thereof | |
US5928648A (en) | Recombinant herpesvirus of turkeys and uses thereof | |
JP4440347B2 (ja) | 組換えキメラウイルスとその使用 | |
JP2000512844A (ja) | ベクターとして鳥類の感染性喉頭気管炎ウイルスを用いた鳥類用組換え生ワクチン | |
AU711813B2 (en) | Avian herpesvirus-based live recombinant avian vaccine, in particular against Gumboro disease | |
US5961982A (en) | Recombinant herpesvirus of turkeys and uses thereof | |
US6913751B2 (en) | Recombinant avian herpesvirus useful in vaccine production | |
US20100008948A1 (en) | Recombinant herpesvirus useful in vaccine production | |
JP3964458B2 (ja) | 組換え型伝染性喉頭気管炎ウイルスおよびその使用 | |
JPH11507241A (ja) | 組換え鶏痘ウイルスおよびその使用 | |
US6410033B1 (en) | Recombinant infectious bovine rhinotracheitis virus | |
JPH09505726A (ja) | 組換え感染性喉頭気管炎ウイルス及びそれらの使用 | |
JP3428666B2 (ja) | 組換えマレック病ウイルスおよびその製法 | |
ES2360298T3 (es) | Herpesvirus recombinantes de pavos y sus usos. | |
JP3675569B2 (ja) | 組み換えウイルス及びそれよりなるワクチン | |
AU684046C (en) | Recombinant herpesvirus of turkeys and uses thereof | |
AU750084B2 (en) | Recombinant herpesvirus of turkeys and uses thereof II |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050322 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050622 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050808 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050921 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A133 Effective date: 20051114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051114 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20051206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20051226 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100106 Year of fee payment: 4 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100106 Year of fee payment: 4 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100106 Year of fee payment: 4 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110106 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120106 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130106 Year of fee payment: 7 |
|
LAPS | Cancellation because of no payment of annual fees |